Suchergebnisse - "Biosimilar insulin"

PubPharm (42)

1

After 100 years of life, is there an insulin crisis? The problem of insulin costs and the opportunity of biosimilar insulins

in: AboutOpen | 2023

von Domenico Cucinotta | Annalisa Giandalia | Giuseppina Russo

2

Effectiveness, safety and treatment adherence of biosimilar follow-on insulin in diabetes management

enthalten in: Diabetes, obesity & metabolism | 2022

von Pham, T. | Chen, X. | Barron, J. | +3

3

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects : Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study

enthalten in: Diabetes, obesity & metabolism | 2022

von Plum-Mörschel, L. | Klein, O. | Singh, G. | +7

4

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M) : A Subgroup Analysis by Prior Type of Premix Insulin

enthalten in: Diabetes therapy : research, treatment and education of diabetes and related disorders | 2022

von Aravind, S. | Singh, K. | Mogylnytska, L. | +8

5

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus

enthalten in: Diabetes, obesity & metabolism | 2022

von Wang, W. | Song, X. | Lou, Y. | +3

6

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin

enthalten in: Diabetes therapy | 2022

von Aravind, S. | Singh, K. | Mogylnytska, L. | +8

7

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin

enthalten in: Diabetes therapy | 2022

von Aravind, S. | Singh, K. | Mogylnytska, L. | +8

8

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin

enthalten in: Diabetes therapy | 2022

von Aravind, S. | Singh, K. | Mogylnytska, L. | +8

9

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects : Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study

enthalten in: Diabetes, obesity & metabolism | 2022

von Plum-Mörschel, L. | Singh, G. | Murugesan, S. | +4

10

Biosimilar insulins in international and domestic practice of pharmacist

in: Фармацевтичний журнал | 2022

von I. O. Vlasenko | I. V. Nizhenkovska

1
2
3
4
5
Nächster »
[5]